The development of noninvasive screening tests would represent a major advance in the fight against cancer, as pre-clinical or early diagnosis could be considered the best weapons to reduce cancer mortality. The use of autoantibodies against cancer autoantigens is a promising alternative to fulfill this goal. Recent progress in protein microarray formats and other proteomic strategies has brought extraordinary opportunities to advance the discovery of new cancer autoantigens. These new approaches have allowed identification of autoantibodies with a higher prevalence, simplifying the development of predictor panels with wider coverage. Still, some issues have to be resolved before clinical application of these results. First, technical limitations in the quality and reproducibility of the microarrays and the statistical tools for data analysis have to be resolved. Second, thorough validation of the candidate biomarkers has to be carried out to include not just one particular cancer type but different cancers and other benign, inflammatory pathologies, which may give rise to cross-reactions and loss of the specificity and sensitivity of the predictive assay. The extraordinary sensitivity of the immune system to detect minor alterations in self-proteins might be used to highlight changes in the cancer protein sequence and structure that can be used for personalized therapy, including immunotherapeutic vaccines. The increasing detection of kinase proteins as autoantibody targets points to new molecules with potential therapeutic impact.
A humoral response to cancer proteins takes place in cancer patients as a consequence of differential expression or modification of self-proteins (i.e. aberrant glycosylation, overexpression, aberrant degradation, hyper-activation, or mutation). [1] The immune response occurs early during tumor development and, as a result, the presence of autoantibodies could enable cancer diagnosis earlier than any other techniques, providing an effective means of cancer screening and preclinical diagnosis. The use of autoantibodies for the diagnosis and prognosis of cancer in serum is becoming a major biomarker discovery tool. From the first report of tumor-associated autoantigens (TAAs) by Old and colleagues, [2] a number of proteomic technologies have been developed in recent years to increase the number and quality of identified candidate TAAs. Multiple advances in biochemical and molecular biology techniques have been applied to the discovery of novel autoantibodies and their respective TAAs. The increase in the tumor antigen repertoire permits the development of more sensitive and accurate diagnostic tools for early cancer screening. Indeed, several high-throughput proteomic strategies have been investigated in different cancers to identify cancer-specific autoantibodies through different methodologies. [3] [4] [5] [6] [7] [8] [9] In this article, we review these methodologies and discuss some of the issues that need to be resolved and clarified before this approach can be used in clinical applications.
Identification of Tumor-Specific Autoantigens
From the initial autologous typing strategy, [2] different technologies have been developed and are widely used to look for autoantibodies and their respective reactive TAAs. Some of the most standard strategies for identifying autoantibodies are serological analysis of recombinant cDNA expression libraries (SEREX), serological proteome analysis (SERPA), and protein microarrays printed with either tumor cell fractions, phage libraries, or human recombinant protein microarrays (figure 1). The pros and cons of these approaches are discussed here briefly.
Serological Analysis of Recombinant cDNA Expression Libraries (SEREX)
An early approach for discovering cancer antigens was SEREX technology. [10] SEREX involves identification of TAAs using phage expression libraries containing cDNA from tumoral tissues or cells, transferred onto membranes for screening with cancer sera. Application of SEREX has resulted in the identification of over 2300 autoantigens recognized by patient sera (e.g. NY-ESO-1 [11] ), which are documented in a public access database. [12] SEREX can be applied to any tumor, delivering immunogenic tumor antigens that are relevant to the disease. The main disadvantage of this technique is that most of the antigens identified by SEREX are linear epitopes corresponding to abundant proteins that are easily expressed in bacteria. No post-translational modifications can be detected. Moreover, most of the candidates remain to be further validated to determine if the responses are disease specific.
Serological Proteome Analysis (SERPA)
The SERPA proteomic technique is a common approach for TAA discovery. It is based on the combination of 2D electrophoresis, western blot analysis, and mass spectrometry. [13] Here, proteins from tumoral samples (either cell lines or tumoral tissues) are resolved in 2D gels and transferred onto membranes for western blot analyses with cancer and healthy control sera. After comparing the immunoreactive profiles, cancer-specific spots are subsequently identified by mass spectrometry. This technology has been successfully used for different cancer types (e.g. pancreatic and lung cancer). [14, 15] The problems associated with this technology are those common to 2D gels: a bias toward identification of abundant proteins, a limited range of proteins resolved in the gel, poor representation and detection of membrane proteins, and detection of linear epitopes as a consequence of the denaturation of the proteins. Both SERPA and SEREX are labor intensive, low throughput, and semiquantitative in nature.
Protein Microarrays
Protein microarrays are appropriate for high-throughput assays. They can be used for the screening of multiple samples, with minimal consumption of serum. They were initially described in 1999, [16] but their use has only recently become widespread following many different technical improvements.
Natural Protein Microarrays
This approach relies on fractionation of tumor cell lysates to separate the cellular proteome into many fractions, which are subsequently blotted onto nitrocellulose membranes or nitrocellulose-coated slides. Then the membranes or arrays are screened with patient and control sera to identify the specific fractions that are differentially recognized by cancer sera. TAAs in the fraction are then identified by mass spectrometry. They can be expressed and verified by other techniques. Improvements in the reproducibility and automation of liquidbased chromatography and microarray spotting have enhanced the use of this technique, which has been used to identify TAAs in several cancers. [7, 17] The advantages of cell fractionation include (i) preservation of the native state of the proteins, including posttranslational modifications; and (ii) detection of human proteins with alternative splicing or mutations, which might be responsible for the binding of the autoantibodies. On the other hand, identification of the specific protein responsible for the antibody binding may be difficult because it is necessary to test the whole fraction, and the antigen could be present at a very low level relative to the other components. Indeed, the protein needs to be expressed and further validated by other techniques. 
Phage Display Libraries
A new and attractive approach for identifying TAAs consists of the combination of phage display and high-throughput screening approaches such as protein microarrays. Cancer cDNA libraries are expressed as fusions to proteins of the capsid of T7 phages. Then several rounds of biopanning are performed for negative and positive selection, using sera from controls and cancer patients, respectively, to enrich the libraries in phages displaying only cancer-specific peptides. After selection, thousands of individual phages are grown, printed in nitrocellulose arrays, and screened with cancer and reference sera to identify those cancer-specific peptides that are recognized by patients' autoantibodies. This approach has proved to be informative in several cancers, including ovarian, prostate, and lung cancer. [3, 9, 18] A variant of this method consists of substitution of tumoral cDNA libraries with random peptide libraries. [19] The advantages of this new methodology are similar to those of SEREX in the use of cDNA derived from tumor and multiplexing capacity, since very small amounts of sera are enough to test hundreds to thousands of phages. Moreover, the highthroughput approach increases the chances of getting an improved TAA panel with better diagnostic accuracy. The limitations of this strategy are also similar to those of SEREX. Most of the identified peptides do not match any known protein sequence. No post-translationally modified peptides or proteins can be detected. However, out-of-frame peptide inserts, truncated gene products, alternative tumor-splicing cDNAs, or rare transcripts can be inserted. [3, 9] Indeed, it has been reported that only 6-8% of a cDNA library may yield clones in the natural open reading frame (ORF). [20] Finally, we should keep in mind that this methodology is very laborious, technically-demanding, and difficult to automate, which has severely limited its application.
Human Open Reading Frame (ORF) Protein Arrays
The human proteome derives from the 23 000 human genes after going through various splicing processes and posttranslational modifications, including phosphorylation, glycosylation, and acetylation. Another approach to identify cancer autoantibodies is based on construction and screening of highdensity protein microarrays printed with similar amounts of naturally occurring human proteins, including either low-or high-abundance proteins. There are two major high-density platforms currently available -the Protoarray Ò , printed with up to approximately 9000 ORFs, [4, 6] and the nucleic acid programmable protein array (NAPPA) [5] -that have been used to identify autoantibodies in cancer. As the collections of human ORF expression repositories are increasing, a human protein array containing all human ORFs could be available in the near future, maximizing the chances of discovery of new TAAs. However, the cost of such devices might be prohibitive for screening purposes. The main advantages of this approach are that the proteins printed in the array are full length, native-like, and known 'a priori', facilitating generation and verification of the results. Moreover, there is no bias toward abundant proteins, since all are printed in similar amounts. The main disadvantages of this approach are associated with cost and batch-to-batch reproducibility, which are common to other protein microarray formats.
An attractive, lower-cost alternative to high-content recombinant protein microarrays is NAPPA, where cDNAs, rather than proteins, are spotted for just-in-time expression using an in vitro transcription and translation system. [21, 22] However, access to large collections of cDNA-expressing clones and reproducible printing conditions might be difficult to achieve for conventional laboratories.
The Possibility of Developing Clinical Diagnostic Prognostic Tests
Despite many reports claiming high specificities and sensitivities (80% or more) obtained with panels of cancer autoantigens in different types of cancer, the clinical application of autoantibodies in cancer diagnosis is still limited by generally low specificity and sensitivity. There are several reasons for this. First, there is a low autoantibody prevalence due to the high variability among cancer patients. Initially, only TAAs such as tumor protein p53 (TP53), MYC, cyclin B, MUC1 or cancer testis antigens have been found to be altered, mutated, or aberrantly expressed in many types of cancer (see Tan and Zhang [23] for a review). Many of the initial reports focused only on these common TAAs, where autoantibodies against a single antigen were found in only 10-30% of patients. For these antigens, the prevalence and the discriminatory power between different cancers is low. The case of TP53 is the paradigm of TAA. Autoantibodies directed against TP53 have been extensively studied since the first identification in 1979. [24] The problem associated with TP53 autoantibodies, which is common to other individual cancer autoantigens, is their poor predictive value or sensitivity. TP53 autoantibodies are not specific for the cancer type, and their sensitivity is around 20% in most cases. However, in a recent study, antibodies to TP53 were detected in 42% of patients with serous ovarian cancer. [25] Moreover, a significant correlation with improved survival was observed in these patients, demonstrating the prognostic value of TP53.
The heterogeneity in the humoral response obliges one to use combinations of biomarkers in order to get acceptable patient coverage and the highest possible specificity. Then multiple cancerspecific autoantibody panels must be tested at the same time to improve both their predictive value and their sensitivity prior to clinical use. However, some novel TAAs have been defined with protein microarrays that seem to have a higher prevalence. [6, 26] These TAAs contain members from many different protein families, including kinases. High specificity is particularly relevant in those cancers with a lower prevalence that require massive screening. [3] Application only to at-risk populations (e.g. the population over 50 years old in the case of colorectal cancer) would increase the predictive accuracy of these assays.
To make a difference compared with current methods, cancer autoantigen-based diagnosis should be applicable before the tumor is large enough to be diagnosed clinically. Application in early diagnosis is the major challenge to be addressed. Some studies have highlighted significant improvements in the diagnostic efficacy of autoantibodies versus conventional serum biomarkers, such as carcinoembryonic antigen for colon cancer, alpha-fetoprotein for liver cancer, or prostate-specific antigen for prostate cancer. In a recent report, Hanash and colleagues [27] reported the existence of autoantibodies to annexin 1, 14-3-3 theta, and laminin receptor 1 (LAMR1) in pre-diagnostic lung cancer sera. Antibodies against these proteins were significantly elevated in pre-clinical sera when compared with those from matched high-risk controls who did not develop lung cancer. These three proteins had been previously identified from natural protein microarrays. Other issues to be resolved before clinical application of autoantibodies are (i) to prove the ability to distinguish not only between cancer and healthy tissue but also between different cancers; [28] and (ii) to prove the ability to distinguish between cancer and other inflammatory and benign diseases that may occur in the subject [29] (figure 2). Although an intensive screening program using sera from these pathologies is necessary, few reports have addressed this problem.
A major hurdle for clinical application is the discrepancy between published reports, probably due to differences in analytical and statistical methodologies. Two recent studies on the identification of autoantibodies in ovarian cancer illustrate this aspect. [4, 30] Although both studies targeted the same disease (ovarian cancer) and used the same approach (protein microarrays printed with recombinant proteins expressed on the baculovirus system), their results were totally different. None of the identified top proteins was coincident. This might be explained by the use of different batches of protein microarrays and the use of different statistical methods to calculate the frequency of the autoantibodies. Both factors are extremely relevant and point out two major issues that need to be resolved and standardized as soon as possible. We can foresee that, as this strategy becomes more popular, better and more focused statistical methods need to be developed. Regarding protein microarrays, more robust platforms have to be developed and standardized. Currently available products present significant variability between batches of the same product (Babel I, personal communication). Again, significant progress needs to be made in this area if these devices are to be used in routine clinical practice, including the quality of the printed proteins, the quality and reproducibility of the surface (i.e. the nitrocellulose type), and content validation.
The peptides proteins used for validation of the candidate biomarkers represent another source of variability in the final diagnostic assay. As was mentioned before, antigens from different sources have been used for the discovery of tumor autoantigens: natural proteins fractionated from tumors, SEREX peptides, phage-peptides, recombinant proteins from Escherichia coli or baculovirus, etc. (figure 3). It seems reasonable that those strategies making use of natural proteins present in the tumor should deliver better results than those based on peptides or E. coli-derived proteins, whose resemblance to the natural antigens is much lower. However, the quality of the antigens affects not only the discovery process but also the validation process. In this regard, most of the validation experiments have been carried out by ELISA or immunodotblot using E. coli-(or phage-) expressed human proteins. [31, 32] It is well known that this system is not the most adequate for the production of native-like human proteins. Validation experiments should be performed with proteins of the highest quality, mimicking the real target as much as possible. Complete biochemical characterization of the cancer proteins -followed by further expression in mammalian systems or, at least, in the baculovirus system -would be far preferable to test the quality of the assay and subsequent implementation of the final test assay.
Potential Use in Personalized Cancer Therapy
None of the current theories (see Bei et al. [33] for a review) fully explains the production of autoantibodies. These theories tend to forget that cancer cells may contain tens or hundreds of mutant genes that are not present in normal tissues. [34] It is unknown how these novel epitopes may influence the host humoral response. Much more research needs to be done in this area. The understanding of this process will be critical for future applications of this strategy in cancer diagnosis and therapy.
The immune system can act as an extremely sensitive reporter for identification of new altered proteins that are different from self-proteins. Therefore, this strategy may help to detect proteins that undergo alterations during the neoplastic process. These proteins might become interesting therapeutic targets. In a recent report, Babel et al. [6] described the occurrence of autoantibodies against a number of kinases in colorectal cancer. In fact, most of the candidate TAAs were kinase proteins. Kinases are common targets for therapeutic drugs such as imatinib, dasatinib, and others. In the same study, a different autoantibody profile was found, depending on the location of the metastasis. Metastasis to different organs (lung, liver) gave rise to different profiles. [6] This prognostic capacity might also be used for therapeutic purposes. Moreover, an association between autoantibody levels and survival has been found in colorectal cancer patients (Babel I, personal communication) and in ovarian and pancreatic cancer patients. [30] Association of individual mutations with antibody responses might be used to tailor treatment according to individual variations. The use of autoantibody profiles has already demonstrated the capacity to classify clinically challenging cohorts of prostate cancer patients. [29] This classification can be used for personalized treatment.
Cancer immunotherapy is the most active pipeline of new products for fighting cancer. There are already multiple chimeric or humanized antibodies that target specific tumor antigens and are used for therapeutic purposes in patients. Still, there is a relative shortage of good targets for immunotherapy. Autoantibody profiling can help in the selection of new antigens that are able to evoke a cytotoxic immune response. They can be used as personalized therapeutic vaccines, according to the individual profiles of the patients obtained by protein microarrays. [35] Autoepitope immunotherapy is a promising approach for personalized therapy. [23] 
Conclusions
The occurrence of autoantibodies in the serum of cancer patients is now a well established and accepted issue after being underestimated for many years. The use of potent proteomic platforms, such as protein microarrays, has contributed enormously to this general acceptance. Despite some experimental variations and limitations that still need to be resolved, the use of cancer autoantigens is a very promising strategy for cancer diagnosis and prognosis, even at very early stages of the disease. A complete survey of cancer autoantigens still needs to be done in more types of cancer, as most current efforts have focused on the most prevalent cancers (lung, prostate, ovarian, colorectal). The capacity of the immune system to detect minor protein alterations, even when present at very low levels, makes this strategy ideal for monitoring and classification of cancer patients, as well as for definition of individual targets in a first step for personalized medicine.
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Mammalian cells + − Fig. 3 . Adequacy of protein expression methods for target validation. In order to get appropriate analogs of the tumor antigens, the quality of the proteins used in diagnostic immunoassays needs to be evaluated. Expression in baculovirus and mammalian cells seems to be the most adequate, as the folding and the post-translational modifications are similar to those of the natural proteins.
